Research & Literature

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.

van Rhee F, Casper C, Voorhees PM, et al.

Oncotarget 2015; (6(30)):30408-19 doi:10.18632/oncotarget.4655.

Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research.

Newman SK, Jayanthan RK, Mitchell GW, et al.

The Yale journal of biology and medicine 2015; (88(4)):383-8.

Castleman Disease: A Rare Condition with Endocrine Manifestations.

Cervantes CE, Correa R

Cureus 2015; (7(11)):e380 doi:10.7759/cureus.380.

A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination.

Kantarci FE, Eren R, Gündoğan C, et al.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2016; (22(7)):483-5.

Complete resection of unicentric Castleman disease in the superior mediastinum: A case report.

Haro A, Kuramitsu E, Fukuyama Y

International journal of surgery case reports 2016; (25()):44-7.

Clinical response to liposomal doxorubicin and rituximab in HHV-8-associated multicentric Castleman's disease in an HIV-positive patient.

Osa M, Maeda T, Misawa K, et al.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2016; (22(12)):804-807 doi:10.1016/j.jiac.2016.06.004.

Castleman Disease of the Thorax: Clinical, Radiologic, and Pathologic Correlation: From the Radiologic Pathology Archives.

Kligerman SJ, Auerbach A, Franks TJ, Galvin JR

Radiographics : a review publication of the Radiological Society of North America, Inc 2016; (36(5)):1309-32 doi:10.1148/rg.2016160076.

International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Fajgenbaum DC, Uldrick TS, Bagg A, et al.

Blood 2017; (129(12)):1646-1657 doi:10.1182/blood-2016-10-746933.

HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH/EAHP Workshop Report-Part 3.

Chadburn A, Said J, Gratzinger D, et al.

American journal of clinical pathology 2017; (147(2)):171-187 doi:10.1093/ajcp/aqw218.

A possible new morphological variant of mantle cell lymphoma with plasma-cell type Castleman disease-like features.

Igawa T, Omote R, Sato H, et al.

Pathology, research and practice 2017; (213(11)):1378-1383 doi:10.1016/j.prp.2017.09.015.

TAFRO Syndrome.

Igawa T, Sato Y

Hematology/oncology clinics of North America 2018; (32(1)):107-118 doi:10.1016/j.hoc.2017.09.009.

POEMS Syndrome: Diagnosis and Investigative Work-up.

Dispenzieri A, Kourelis T, Buadi F

Hematology/oncology clinics of North America 2018; (32(1)):119-139 doi:10.1016/j.hoc.2017.09.010.

The Role of Interleukin-6 in Castleman Disease.

Yoshizaki K, Murayama S, Ito H, Koga T

Hematology/oncology clinics of North America 2018; (32(1)):23-36 doi:10.1016/j.hoc.2017.09.003.

Pathology of Castleman Disease.

Wu D, Lim MS, Jaffe ES

Hematology/oncology clinics of North America 2018; (32(1)):37-52 doi:10.1016/j.hoc.2017.09.004.

Unicentric Castleman Disease.

Wong RSM

Hematology/oncology clinics of North America 2018; (32(1)):65-73 doi:10.1016/j.hoc.2017.09.006.

Recurrence in unicentric castleman's disease postoperatively: a case report and literature review.

Ren N, Ding L, Jia E, Xue J

BMC surgery 2018; (18(1)):1 doi:10.1186/s12893-017-0334-7.

Idiopathic multicentric Castleman's disease: a clinicopathologic study in comparison with IgG4-related disease.

Otani K, Inoue D, Fujikura K, et al.

Oncotarget 2018; (9(6)):6691-6706 doi:10.18632/oncotarget.24068.

Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome.

Ozeki T, Tsuji M, Yamamoto J, et al.

CEN case reports 2018; (7(2)):243-247 doi:10.1007/s13730-018-0338-x.

Linking young men who have sex with men (YMSM) to STI physicians: a nationwide cross-sectional survey in China.

Cao B, Zhao P, Bien C, et al.

BMC infectious diseases 2018; (18(1)):228 doi:10.1186/s12879-018-3145-2.

Castleman disease versus lymphoma in neck lymph nodes: a comparative study using contrast-enhanced CT.

Li J, Wang J, Yang Z, et al.

Cancer imaging : the official publication of the International Cancer Imaging Society 2018; (18(1)):28 doi:10.1186/s40644-018-0163-7.

Castleman disease: Case series of two surgical patients from different ends of the disease spectrum with literature review.

C G RR, B S

International journal of surgery case reports 2018; (53()):163-167 doi:10.1016/j.ijscr.2018.10.053.

Multicentric Castleman's disease: Report of three cases.

Guazzaroni M, Bocchinfuso F, Vasili E, et al.

Radiology case reports 2019; (14(3)):328-332 doi:10.1016/j.radcr.2018.10.005.

Kaposi sarcoma-associated herpesvirus/human herpesvirus 8-associated lymphoproliferative disorders.

Oksenhendler E, Boutboul D, Galicier L

Blood 2019; (133(11)):1186-1190 doi:10.1182/blood-2018-11-852442.

Unicentric Castleman's disease located between the aorta and inferior vena cava: A case report.

Murata M, Nagano O, Hasegawa G, et al.

SAGE open medical case reports 2019; (7()):2050313X19839532 doi:10.1177/2050313X19839532.

POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.

Dispenzieri A

American journal of hematology 2019; (94(7)):812-827 doi:10.1002/ajh.25495.

Imaging and clinical features of Castleman Disease.

Zhao S, Wan Y, Huang Z, et al.

Cancer imaging : the official publication of the International Cancer Imaging Society 2019; (19(1)):53 doi:10.1186/s40644-019-0238-0.

Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Thymidine Kinase (ORF21) by X-Box Binding Protein 1.

Wang V, Davis DA, Deleage C, et al.

Journal of virology 2020; (94(5)) doi:10.1128/JVI.01555-19.

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.

van Rhee F, Casper C, Voorhees PM, et al.

The Lancet. Haematology 2020; (7(3)):e209-e217 doi:10.1016/S2352-3026(19)30257-1.

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.

Min GJ, Jeon YW, Park SS, et al.

The Korean journal of internal medicine 2021; (36(2)):424-432 doi:10.3904/kjim.2019.330.

Overview of Castleman disease.

Dispenzieri A, Fajgenbaum DC

Blood 2020; (135(16)):1353-1364 doi:10.1182/blood.2019000931.

Density and size of lymphoid follicles are useful clues in differentiating primary intestinal follicular lymphoma from intestinal reactive lymphoid hyperplasia.

Li HN, Wang RC, Chen JP, et al.

Diagnostic pathology 2020; (15(1)):82 doi:10.1186/s13000-020-00991-3.

Cutaneous manifestations of Castleman disease.

Chavez-Alvarez S, Villarreal-Martinez A, Ocampo-Candiani J, et al.

International journal of dermatology 2020; (59(10)):1226-1240 doi:10.1111/ijd.15043.

Interleukin-6-producing Intravascular Large B-cell Lymphoma with Lymphadenopathy Mimicking the Histology of Multicentric Castleman Disease.

Shiroshita K, Kikuchi T, Okayama M, et al.

Internal medicine (Tokyo, Japan) 2020; (59(23)):3061-3065 doi:10.2169/internalmedicine.5046-20.

A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.

Yu L, Shi M, Cai Q, et al.

The oncologist 2020; (25(11)):963-973 doi:10.1634/theoncologist.2019-0986.

Five biopsies, one diagnosis: challenges in idiopathic multicentric Castleman disease.

Semenchuk J, Merchant A, Sakhdari A, Kukreti V

BMJ case reports 2020; (13(11)) doi:10.1136/bcr-2020-236654.

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

van Rhee F, Oksenhendler E, Srkalovic G, et al.

Blood advances 2020; (4(23)):6039-6050 doi:10.1182/bloodadvances.2020003334.

Updates on the diagnosis and management of multicentric Castleman disease.

Wu YJ, Su KY

Tzu chi medical journal 2021; (33(1)):22-28 doi:10.4103/tcmj.tcmj_15_20.

Coexistence of disseminated Kaposi sarcoma and multicentric Castleman disease in an HIV-infected patient under viral suppression.

Lin IF, Lin JN, Tsai TH, et al.

International journal of STD & AIDS 2021; (32(3)):286-289 doi:10.1177/0956462420968385.

Castleman disease: A single-center case series.

Pribyl K, Vakayil V, Farooqi N, et al.

International journal of surgery case reports 2021; (80()):105650 doi:10.1016/j.ijscr.2021.105650.

Emerging role of 18F-FDG PET/CT in Castleman disease: a review.

Koa B, Borja AJ, Aly M, et al.

Insights into imaging 2021; (12(1)):35 doi:10.1186/s13244-021-00963-1.

POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management.

Dispenzieri A

American journal of hematology 2021; (96(7)):872-888 doi:10.1002/ajh.26240.

Image-guided lymph node fine-needle aspiration: the Johns Hopkins Hospital experience.

Shyu S, Rajgariah A, Saoud C, et al.

Journal of the American Society of Cytopathology 2021; (10(6)):543-557 doi:10.1016/j.jasc.2021.04.004.

Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease.

Arakawa A, Iizuka M, Matsuda S, et al.

Internal medicine (Tokyo, Japan) 2021; (60(24)):3995-3998 doi:10.2169/internalmedicine.6938-20.

Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease.

Goodman AM, Jeong AR, Phillips A, et al.

European journal of haematology 2021; (107(6)):642-649 doi:10.1111/ejh.13702.

A retrospective study of 44 patients with head and neck Castleman's disease.

Wang T, Chen X, Chen W, et al.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2022; (279(5)):2625-2630 doi:10.1007/s00405-021-07065-0.

[Unicentric Castleman disease: a blind lymph node.]

Rizzi S, Polenzani I, Troisi A, et al.

Recenti progressi in medicina 2021; (112(10)):653-658 doi:10.1701/3679.36656.

A Rare Lymphoproliferative Disease: Castleman Disease

Gündüz E, Özdemir N, Bakanay ŞM, Karakuş S

Turkish journal of haematology : official journal of Turkish Society of Haematology 2021; (38(4)):314-320 doi:10.4274/tjh.galenos.2021.2021.0440.

Castleman disease.

Carbone A, Borok M, Damania B, et al.

Nature reviews. Disease primers 2021; (7(1)):84 doi:10.1038/s41572-021-00317-7.

Castleman disease and TAFRO syndrome.

Masaki Y, Arita K, Sakai T, et al.

Annals of hematology 2022; (101(3)):485-490 doi:10.1007/s00277-022-04762-6.

Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.

Lang E, Sande B, Brodkin S, van Rhee F

Therapeutic advances in hematology 2022; (13()):20406207221082552 doi:10.1177/20406207221082552.

Multicentric Castlemans disease. Symptoms, diagnostics and therapy.

Adam Z, Řehák Z, Adamová Z, et al.

Vnitrni lekarstvi 2022; (68(1)):41-53.

Unicentric Castlemans disease. Symptoms, diagnostics and therapy.

Adam Z, Řehák Z, Adamová Z, et al.

Vnitrni lekarstvi 2021; (67(8)):465-473.

Treatment and Outcome of Castleman Disease: A Retrospective Report of 31 Patients.

Tang D, Guo Y, Tang Y, Wang H

Therapeutics and clinical risk management 2022; (18()):499-509 doi:10.2147/TCRM.S354130.

Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review.

Rehman MEU, Chattaraj A, Neupane K, et al.

European journal of haematology 2022; (109(4)):309-320 doi:10.1111/ejh.13823.

Systemic lupus erythematosus mimicking idiopathic multicentric Castleman disease: A diagnostic dilemma.

Gunathilake K, Rifath M, Munasinghe BM, et al.

SAGE open medical case reports 2022; (10()):2050313X221106110 doi:10.1177/2050313X221106110.

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.

Pierson SK, Katz L, Williams R, et al.

Nature communications 2022; (13(1)):7236 doi:10.1038/s41467-022-34873-7.

Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report.

Kakutani T, Nunokawa T, Chinen N, Tamai Y

Medicine 2022; (101(48)):e32200 doi:10.1097/MD.0000000000032200.

Title not available

Bertinchamp R, Terriou L

La Revue de medecine interne 2022; (43(10S1)):10S4-10S9 doi:10.1016/S0248-8663(23)00019-X.

Idiopathic multicentric Castleman disease in an adolescent diagnosed following COVID-19 infection.

Mosleh E, Mehta S, Young E, et al.

Pediatric blood & cancer 2023; (70(6)):e30239 doi:10.1002/pbc.30239.

Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

Derry-Vick HM, Heathcote LC, Glesby N, et al.

Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

Medicaid coverage and access to obstetrics and gynecology subspecialists: findings from a national mystery caller study in the United States.

Corbisiero MF, Tolbert B, Sanches M, et al.

American journal of obstetrics and gynecology 2023; (228(6)):722.e1-722.e9 doi:10.1016/j.ajog.2023.03.004.

Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

Dunsmore VJ, Neupert SD

Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

Scanxiety Conversations on Twitter: Observational Study.

Bui KT, Li Z, Dhillon HM, et al.

JMIR cancer 2023; (9()):e43609 doi:10.2196/43609.

An economic evaluation of fine-needle cytology as the primary diagnostic tool in the diagnosis of lymphadenopathy.

Cavallo M, Ciliberti V, Maffei E, et al.

Open medicine (Warsaw, Poland) 2023; (18(1)):20230719 doi:10.1515/med-2023-0719.

Expert consensus on the integrated diagnosis of idiopathic multicentric Castleman disease.

Montes-Moreno S, Climent F, Fraga M, et al.

Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia 2023; (56(3)):158-167 doi:10.1016/j.patol.2022.12.003.

Clinical features and outcomes in patients with human immunodeficiency virus-negative, Castleman's disease: a single medical center study in Tunisia.

Chabchoub I, Salah RB, Kallel R, et al.

Romanian journal of internal medicine = Revue roumaine de medecine interne 2024; (62(1)):20-32 doi:10.2478/rjim-2023-0028.

The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features.

Pelliccia S, Rogges E, Cardoni A, et al.

British journal of haematology 2024; (204(2)):534-547 doi:10.1111/bjh.19171.

Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.

Bustamante MS, Pierson SK, Ren Y, et al.

Haematologica 2024; (109(7)):2196-2206 doi:10.3324/haematol.2023.283603.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.

Gao YH, Liu YT, Zhang MY, et al.

British journal of haematology 2024; (204(5)):1830-1837 doi:10.1111/bjh.19334.

TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?

Takai K

Biomedicines 2024; (12(3)) doi:10.3390/biomedicines12030652.

Successful outcome in a case of idiopathic multicentric Castleman disease with atypical lymphadenopathy and kidney injury: Diagnostic challenges and treatment approach-Case report.

Yalikun D, Zhuang J, Lei W, et al.

SAGE open medical case reports 2024; (12()):2050313X241240097 doi:10.1177/2050313X241240097.

Castleman disease of the renal hilum: A rare case report.

Yaynishet YA, Abera MT, Reta BK, et al.

Radiology case reports 2024; (19(8)):3130-3135 doi:10.1016/j.radcr.2024.04.053.

IL-6 Blockade in Cytokine Storm Syndromes.

Barrett D

Advances in experimental medicine and biology 2024; (1448()):565-572 doi:10.1007/978-3-031-59815-9_37.

Idiopathic multicentric Castleman disease-TAFRO after COVID-19: A case report.

Shiina T, Yamamoto EK, Yamada H, et al.

Modern rheumatology case reports 2025; (9(1)):174-178 doi:10.1093/mrcr/rxae045.

Peculiar hyper vascular manifestations in idiopathic multicentric castleman disease without tafro syndrome: a case report.

Jilani RK, Saleem MR, Akhtar S, Jawad W

Annals of hematology 2024; (103(12)):5929-5934 doi:10.1007/s00277-024-06040-z.

Idiopathic multicentric Castleman disease.

Chaudhari V, Thakkar SJ, Padwal N, Karnik N

Journal of cancer research and therapeutics 2024; (20(5)):1602-1604 doi:10.4103/jcrt.jcrt_2190_22.

Multicentric Castleman Disease: A Case Report of an Arab Female.

Mansour MK, Zayat AS

Cureus 2024; (16(10)):e71112 doi:10.7759/cureus.71112.

Castleman disease-type histopathological patterns of lymph nodes in patients with plasma cell neoplasia and POEMS syndrome.

Rodriguez-Merino L, Montes-Moreno S

Annals of diagnostic pathology 2025; (74()):152414 doi:10.1016/j.anndiagpath.2024.152414.

Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy.

Nijim S, Fajgenbaum DC

Hematology. American Society of Hematology. Education Program 2024; (2024(1)):582-593 doi:10.1182/hematology.2024000582.

Challenging diagnosis: unusual presentation of Unicentric Castleman disease-a case report.

Janoud OK, Alok RE, Amer KA, et al.

Oxford medical case reports 2025; (2025(2)):omae181 doi:10.1093/omcr/omae181.

Pelvic unicentric Castleman's disease mimicking accessory spleen: A rare presentation of Castleman's disease, a case report and literature report.

Emiru ZA, Getahun AM, Kassie YG, et al.

International journal of surgery case reports 2025; (129()):111177 doi:10.1016/j.ijscr.2025.111177.

Successful Treatment of TAFRO (Thrombocytopenia, Anasarca, Fever, Renal Insufficiency, and Organomegaly) Syndrome With Triple Combination Therapy of Corticosteroid, Tocilizumab, and Cyclosporine: A Case Report.

Morino J, Hirai K, Yoshida K, et al.

Cureus 2025; (17(3)):e80274 doi:10.7759/cureus.80274.

[Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report].

Yi P, Zhang XX, Tang T, et al.

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2025; (27(5)):613-617 doi:10.7499/j.issn.1008-8830.2412050.

The morphological spectrum of Castleman disease and related disorders: a report from the Lymphoma Workshop of the 22nd Meeting of the European Association of Hematopathology.

Gasljevic G, Bonometti A, Anagnostopoulos I, et al.

Virchows Archiv : an international journal of pathology 2025; (487(2)):253-273 doi:10.1007/s00428-025-04171-w.

Development and implementation of the International AIDA Network Castleman's disease registry.

Vitale A, Sbalchiero J, Caggiano V, et al.

Frontiers in medicine 2025; (12()):1579182 doi:10.3389/fmed.2025.1579182.

Comparative analysis on efficacy of lymph node sampling through whole node excision versus core needle biopsy: focusing on diagnostic yield for interpretation.

Singh N, Mishra S, Balasubramanian P, et al.

Journal of hematopathology 2025; (18(1)):46 doi:10.1007/s12308-025-00662-6.

Diagnostic and therapeutic challenges in hyaline-vascular idiopathic multicentric Castleman disease: A case report.

Lu C, Ma X, Liu B, et al.

The Journal of international medical research 2025; (53(10)):3000605251381574 doi:10.1177/03000605251381574.

Clinical Presentation, Treatment, and Outcomes of 28 Patients With Castleman Disease: A Retrospective Analysis of an Italian Cohort.

Cristinelli C, Merli M, Lucioni M, et al.

EJHaem 2025; (6(6)):e70158 doi:10.1002/jha2.70158.

Advances in KSHV Research: Molecular Pathogenesis, Immune Evasion, and Evolving Therapeutic Horizon.

Nasir MW, Gao Y

Journal of medical virology 2025; (97(11)):e70695 doi:10.1002/jmv.70695.

"You Always Worry": Scan-Related Anxiety Among Patients With Metastatic Lung Cancer.

Derry-Vick H, Prigerson HG, Hahne J, et al.

Journal of the American College of Radiology : JACR 2025; (22(12)):1572-1577 doi:10.1016/j.jacr.2025.08.021.

Castleman Disease in a Child: A Rare Cause of Persistent Cervical Lymphadenopathy.

Dutta A, Sarma D, Medhi P, et al.

Cureus 2025; (17(11)):e96352 doi:10.7759/cureus.96352.

Dysregulated lymphocyte localization in idiopathic multicentric Castleman disease.

Mumau MD, Gonzalez MV, Forsyth KS, et al.

bioRxiv : the preprint server for biology 2025; doi:10.64898/2025.12.12.693846.

Role of immunohistochemistry in differentiating between reactive and malignant lymphoid hyperplasia - A cross-sectional study.

Chourasia S, Badkur S, Kumar A, Shah M

Bioinformation 2025; (21(10)):3470-3474 doi:10.6026/973206300213470.

Unicentric Castleman disease with paraneoplastic pemphigus in a young woman: a case report.

Lv GT, Zhao YH, Zhao JL, et al.

Frontiers in medicine 2025; (12()):1749601 doi:10.3389/fmed.2025.1749601.

Snapshot Look at Castleman Disease.

Jitaru C, Zlampa N, Dima D, et al.

Journal of cellular and molecular medicine 2026; (30(3)):e70961 doi:10.1111/jcmm.70961.

Severe polyneuropathy in HIV-negative human herpesvirus 8-associated multicentric Castleman disease successfully treated with rituximab and liposomal doxorubicin.

Takahashi S, Yoshihara K, Fujii T, et al.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2026; (32(4)):102934 doi:10.1016/j.jiac.2026.102934.

Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Pelliccia S, Di Rocco A, Palumbo G, et al.

Frontiers in oncology 2026; (16()):1762473 doi:10.3389/fonc.2026.1762473.